EFX has dropped 12% in a week and 28% in a month, yet the lending market is barely registering the selloff as a short-side opportunity.
Options traders have moved firmly into defensive territory. The put/call ratio is running at 1.79, close to its 52-week high of 1.82 and well above the 20-day average of 1.43. That is roughly 1.2 standard deviations above the recent norm, the most pronounced lean toward downside protection Equifax options have shown all year. The shift is sharp: through the first two weeks of September, the PCR was sitting below 1.0. It has since almost doubled. Short interest, by contrast, tells a quieter story. At 6.1% of the free float, it has drifted up about 4% over the month but remains far from extreme. Borrow availability is loose, with 73 million shares still available against the roughly 7.5 million currently borrowed. Cost to borrow has actually eased 13% over the week to 0.36%, hardly the signal of a borrow squeeze. The setup reads as: options traders hedging aggressively, short sellers adding gradually but not piling in.
The Street still leans bullish but is trimming. The consensus mean price target of $213 implies more than 50% upside from the current $140.83, though that gap reflects how far the stock has fallen rather than a sudden surge in conviction. This week, BMO Capital maintained its Market Perform rating but cut its target from $179 to $160, the first coverage-level target closer to where the stock actually trades. Wells Fargo held its Overweight in late September and cut to $200 from $212. Both moves point in the same direction: bulls staying in their seats but lowering their sights. Analyst differentiation rank is in the 97th percentile, an unusually wide spread of opinion across the Street. Forward earnings estimates are still moving upward, with the 12-month forward EPS revision score in the 77th percentile, a notable contradiction with what the price action suggests the market believes. The EV/EBITDA multiple has compressed by about 0.34 turns over the past 30 days to 9.3x, tracking the share price lower. The P/E has contracted five points over the same period to 14.5x.
The bear case centers on mortgage origination volumes. Equifax's revenue mix is more sensitive to US mortgage activity than peers like TRU or ADP, and the stock's underperformance reflects that. Over the past week, TransUnion fell 10.5%, tracking Equifax fairly closely. PAYX dropped 13.3%, suggesting the selloff has spread beyond credit bureau names into payroll and HR data. BR and ADP fell only 1.3% and 2.9% respectively, underlining that the steeper declines are concentrated in names with heavier exposure to origination and financial data cycles. The bull case rests on USIS revenue growth holding in the mid-single digits, EBITDA margin expansion of around 100 basis points year-over-year, and the thesis that mortgage volumes recover as rate conditions ease. Neither outcome is priced with certainty at current levels.
Insider activity over the past 90 days skews negative, though context matters. The CFO sold 4,500 shares in early September at $187.96, and the CEO exercised and sold a net of roughly 26,000 shares in late July at prices around $172 to $175, realising approximately $5.6 million in net proceeds. All trades were executed under pre-arranged 10b5-1 plans, which removes much of the sentiment signal. Planned sales on a schedule are compensation mechanics, not conviction. The 90-day net across insiders is negative 42,291 shares, valued at approximately $7.4 million, but the 10b5-1 framing applies throughout.
Earnings are scheduled for October 21. The last print, in July, sent the stock down 5.3% on the day before a partial recovery of 3.9% over the following five sessions. That pattern, a sharp initial decline followed by a bounce, has appeared before. Whether the options positioning currently priced into the name reflects a similar setup or something more prolonged is what the next three weeks will clarify.
See the live data behind this article on ORTEX.
Open EFX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
